Kiora Pharmaceuticals, Inc.
KPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 35.6% | – | – | – |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 22.5% | – | – | – |
| EPS Diluted | 0.87 | -24.25 | -18.55 | -68 |
| % Growth | 103.6% | -30.7% | 72.7% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |